Fluticasone propionate 100μg bd (FP100) has significantly less effect than budesonide 200μg bd (BUD200) on childhood growth over 1 year of treatment in asthmatics

A. C. Ferguson, H. P. Van Bever, A. M. Teper, O. I. Lasytsya, P. J. Whitehead (Vancouver, Canada; Antwerp, Belgium; Buenos Aires, Argentina; Kiev, Ukraine; Uxbridge, United Kingdom)

Source: Annual Congress 2002 - Safety and efficacy of inhaled corticosteroids in children
Session: Safety and efficacy of inhaled corticosteroids in children
Session type: Oral Presentation
Number: 1447
Disease area: Airway diseases, Paediatric lung diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
A. C. Ferguson, H. P. Van Bever, A. M. Teper, O. I. Lasytsya, P. J. Whitehead (Vancouver, Canada; Antwerp, Belgium; Buenos Aires, Argentina; Kiev, Ukraine; Uxbridge, United Kingdom). Fluticasone propionate 100μg bd (FP100) has significantly less effect than budesonide 200μg bd (BUD200) on childhood growth over 1 year of treatment in asthmatics. Eur Respir J 2002; 20: Suppl. 38, 1447

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
12 weeks comparing salmeterol/fluticasone proprionate (SFC, 50/100 microg b.d. diskus) versus fluticasone proprionate (FP, 250 microg b.i.diskus) as first-line regular asthma treatment
Source: Eur Respir J 2003; 22: Suppl. 45, 236s
Year: 2003

Evaluation of long-term safety, growth and efficacy of fluticasone propionate 100mcg bd compared with sodium cromoglycate 5mg qds in asthmatic children aged 12-47 months
Source: Eur Respir J 2002; 20: Suppl. 38, 219s
Year: 2002

Low-dose (100 μg, b.i.d.) inhaled fluticasone propionate (FP) is as effective as high-dose (500 μg, b.i.d.) in mild symptomatic asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 96s
Year: 2001

Salmeterol/fluticasone propionate combination 50/100 μg bid is more effective than fluticasone propionate 100 μg bid plus montelukast 10 mg once daily in reducing exacerbations
Source: Eur Respir J 2001; 18: Suppl. 33, 262s
Year: 2001

Lower systemic exposure to corticosteroid for fluticasone propionate/salmeterol (500/50mcg bd) compared to budesonide/formoterol (400/12mcg bd) administered via combination dry powder inhalers in subjects with COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 205s
Year: 2006

The effects of fluticasone propionate/salmeterole 50/100 μg bid in children with asthma versus beclometasone propionate 200 μg BD and fluticasone propionate 100 μg bid dry powder inhaletors
Source: Eur Respir J 2004; 24: Suppl. 48, 378s
Year: 2004

Ciclesonide once daily (80 mg/d, 160 mg/d) versus fluticasone propionate twice daily (250 mg/d) in the treatment of patients with persistent asthma
Source: Annual Congress 2010 - Treatment options for asthma
Year: 2010

The salmeterol/fluticasone propionate combination 50/100 μg bid is more effective than oral montelukast 10 mg od as a first line therapy in mild and moderate asthmatics
Source: Eur Respir J 2001; 18: Suppl. 33, 262s
Year: 2001

The effect of two month's treatment with fluticasone (F) at a dose of 500 mg per day versus fluticasone at a dose of 250 mg per day plus salmeterol (S) 100 mg per day in patients with moderate asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 302s
Year: 2002

Seasonality of asthma exacerbations: efficacy of fluticasone furoate/vilanterol 100/25µg (FF/VI) vs fluticasone furoate 100µg (FF) alone
Source: International Congress 2017 – Asthma management
Year: 2017


Comparison of ciclesonide once daily (80 μg/d, 160 μg/d) and fluticasone propionate twice daily (176 μg/d) in the treatment of children with persistent asthma
Source: Eur Respir J 2007; 30: Suppl. 51, 457s
Year: 2007

Comparison of ciclesonide (MDI) once daily and fluticasone propionate (Diskus®) twice daily in the treatment of patients with moderate asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 666s
Year: 2006

Erdosteine 600mg, but not placebo and NAC 1200mg, restores airway response to inhaled salbutamol 200mcg in COPD
Source: Annual Congress 2007 - Mechanisms and new treatments of COPD
Year: 2007


Salmeterol/fluticasone propionate combination (SFC) versus doubling dose of fluticasone propionate (FP) in children with asthma insufficiently controlled on moderate doses of inhaled corticosteroids
Source: Annual Congress 2010 - Managing asthma and allergic disease in children
Year: 2010


Variability in asthma and treatment efficacy as determined by weekly response rates with fluticasone propionate/salmeterol 100/50mcg (FSC) compared with montelukast 10mg (MON)
Source: Eur Respir J 2003; 22: Suppl. 45, 259s
Year: 2003

"Stepping down" in mild-to-moderate asthmatic children, being well controlled while receiving low doses of inhaled corticosteroids (ICS): nedocromil sodium (NS) vs. fluticasone propionate (FP) 100 mcg/day given either twice
Source: Eur Respir J 2006; 28: Suppl. 50, 713s
Year: 2006

Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) once daily (OD) for 24 weeks in persistent asthma
Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma
Year: 2012

Efficacy of combination fluticasone furoate/vilanterol (FF/VI) and salmeterol/fluticasone propionate (SFC) over 12 weeks in patients with COPD
Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights
Year: 2012

Higher cellular retention and activity after pulse exposure by budesonide (BUD) than fluticasone propionate (FP) and mometasone furoate (MF)
Source: Eur Respir J 2001; 18: Suppl. 33, 158s
Year: 2001

Fluticasone furoate (FF), a novel inhaled corticosteroid (ICS), demonstrates once-daily (OD) efficacy in asthma when dosed in the evening
Source: Annual Congress 2010 - New treatments for asthma and COPD
Year: 2010